NCT06674135View on ClinicalTrials.gov

Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh

PHASE4CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions
Type I Diabetes
Interventions
DRUG

biosimilar insulin glargine

Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe

Trial Locations (1)

Unknown

BIRDEM, the Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Dhaka

All Listed Sponsors
collaborator

Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders

OTHER

collaborator

BADAS-Centre for Health Research and Implementation

UNKNOWN

collaborator

Diabetic Association of Bangladesh (BADAS)

UNKNOWN

lead

Life for a Child Program, Diabetes Australia

OTHER